Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | RHEB | Q15382 | 1/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12939044 | 0.93 | BRD4 (0.70) | BRD4KMT2AMEN1NPC1RAB9A | |
| SCHEMBL20427872 | 0.83 | BRD4 (0.49) | BRD4KMT2AMEN1NPC1RAB9A | |
| SCHEMBL1578341 | 0.83 | BRD4 (0.48) | BRD4KMT2AMEN1NPC1RAB9A | |
| SCHEMBL1578001 | 0.82 | MAPT (0.56) | BRD4NPC1RAB9AALDH1A1KDM4E | |
| Hydroxyamine SCHEMBL1578310 | 0.80 | MAPT (0.53) | BRD4NPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL1578000 | 0.79 | HPGD (0.52) | BRD4KMT2AMEN1NPC1RAB9A | |
| SCHEMBL12966763 | 0.78 | CYP1A2 (0.53) | BRD4CYP1A2CYP2C19TSHRSMN1; SMN2 | |
| SCHEMBL2942849 | 0.77 | BRD4 (0.44) | BRD4NPC1RAB9ACYP1A2CYP2C19 | |
| SCHEMBL1577761 | 0.76 | RAB9A (0.56) | KMT2AMEN1NPC1RAB9ACYP1A2 | |
| SCHEMBL12939033 | 0.75 | MAPT (0.56) | BRD4NPC1RAB9AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11234987-B2 | Isoxazole compounds as inhibitors of heat shock proteins | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-02-01 | — | — | US | disclosed |
| US-10413550-B2 | Isoxazole compounds as inhibitors of heat shock proteins | THE INSTITUTE OF CANCER RESEARCH (GB) | 2019-09-17 | — | — | US | disclosed |
| US-10413550-B2 | Isoxazole compounds as inhibitors of heat shock proteins | THE INSTITUTE OF CANCER RESEARCH (GB) | 2019-09-17 | — | — | US | disclosed |
| US-20170326152-A1 | Isoxazole Compounds As Inhibitors Of Heat Shock Proteins | VERNALIS DEVELOPMENT LIMITED (GB) | 2017-11-16 | — | — | US | disclosed |
| US-20170326152-A1 | Isoxazole Compounds As Inhibitors Of Heat Shock Proteins | VERNALIS DEVELOPMENT LIMITED (GB) | 2017-11-16 | — | — | US | disclosed |
| US-9718793-B2 | Isoxazole compounds as inhibitors of heat shock proteins | VERNALIS (R&D) LTD. (GB) | 2017-08-01 | — | — | US | disclosed |
| US-20130289026-A1 | Isoxazole Compounds As Inhibitors Of Heat Shock Proteins | VERNALIS DEVELOPMENT LIMITED (GB) | 2013-10-31 | — | — | US | disclosed |
| US-8507480-B2 | Isoxazole compounds as inhibitors of heat shock proteins | VERNALIS (R&D) LIMITED (GB) | 2013-08-13 | — | — | US | disclosed |
| US-8507480-B2 | Isoxazole compounds as inhibitors of heat shock proteins | VERNALIS (R&D) LIMITED (GB) | 2013-08-13 | — | — | US | disclosed |
| US-8450310-B2 | Isoxazole compounds as inhibitors of heat shock proteins | VERNALIS (R&D) LIMITED (GB) | 2013-05-28 | — | — | US | disclosed |
| US-20120252797-A1 | Isoxazole Compounds As Inhibitors Of Heat Shock Proteins | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
| EP-1611112-B1 | ISOXAZOLE COMPOUNDS AS INHIBITORS OF HEAT SHOCK PROTEINS | VERNALIS CAMBRIDGE LTD (GB) | 2012-08-22 | — | — | EP | disclosed |
| US-20100179138-A1 | Isozazole Compounds As Inhibitors Of Heat Shock Proteins | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-07-15 | — | — | US | disclosed |
| US-20100179138-A1 | Isozazole Compounds As Inhibitors Of Heat Shock Proteins | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-07-15 | — | — | US | disclosed |
| US-7705027-B2 | Isoxazole compounds as inhibitors of heat shock proteins | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-04-27 | — | — | US | disclosed |
| US-7705027-B2 | Isoxazole compounds as inhibitors of heat shock proteins | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-04-27 | — | — | US | disclosed |
| US-20060241106-A1 | Isoxazole compounds as inhibitors of heat shock proteins | VERNALIS DEVELOPMENT LIMITED (GB) | 2006-10-26 | — | — | US | disclosed |
| EP-1611112-A1 | ISOXAZOLE COMPOUNDS AS INHIBITORS OF HEAT SHOCK PROTEINS | Vernalis (Cambridge) Limited (GB) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004072051-A1 | ISOXAZOLE COMPOUNDS AS INHIBITORS OF HEAT SHOCK PROTEINS | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252797-A1 | Isoxazole Compounds As Inhibitors Of Heat Shock Proteins | HSP90AB1, HSP90AB2P, HSP90AA1 | BRD4 1328/4885KMT2A 4449/4885MEN1 4170/4885 |
| US-20100179138-A1 | Isozazole Compounds As Inhibitors Of Heat Shock Proteins | HSP90AB1, HSP90AA1, HSP90AB2P | BRD4 2216/4885KMT2A 3059/4885MEN1 4710/4885 |
| US-20130289026-A1 | Isoxazole Compounds As Inhibitors Of Heat Shock Proteins | HSP90AB1, HSP90AA1, HSP90AB2P | BRD4 2407/4885KMT2A 3059/4885MEN1 4630/4885 |
| US-20170326152-A1 | Isoxazole Compounds As Inhibitors Of Heat Shock Proteins | HSP90AB1, HSP90AA1, HSP90AB2P | BRD4 2407/4885KMT2A 3059/4885MEN1 4630/4885 |
| US-20060241106-A1 | Isoxazole compounds as inhibitors of heat shock proteins | HSP90AB1, HSP90AA1, HSP90AB2P | BRD4 2126/4885KMT2A 3293/4885MEN1 4582/4885 |
| US-10413550-B2 | Isoxazole compounds as inhibitors of heat shock proteins | HSP90AB1, HSP90AA1, HSP90AB2P | BRD4 2399/4885KMT2A 3105/4885MEN1 4645/4885 |
| US-11234987-B2 | Isoxazole compounds as inhibitors of heat shock proteins | HSP90AB1, HSP90AA1, HSP90AB2P | BRD4 2407/4885KMT2A 3059/4885MEN1 4630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.